Show overview
Oncology Data Advisor has been publishing since 2021, and across the 5 years since has built a catalogue of 448 episodes. That works out to roughly 110 hours of audio in total. Releases follow a several-times-a-week cadence.
Episodes typically run ten to twenty minutes — most land between 7 min and 17 min — though episode length varies meaningfully from one episode to the next. None of the episodes are flagged explicit by the publisher. It is catalogued as a EN-language Science show.
The show is actively publishing — the most recent episode landed 2 weeks ago, with 21 episodes already out so far this year. The busiest year was 2023, with 166 episodes published. Published by Oncology Data Advisor®.
From the publisher
The mission of Oncology Data Advisor is to provide the multidisciplinary team with expert insights into clinical best practices and research progress in cancer care.
Latest Episodes
View all 448 episodesMultidisciplinary Realities: Tumor Board vs Tuesday Afternoon
The Real World vs The Trial Patient: Bridging the Gap
AI-Driven Pathological Subtyping for Pancreatic Cancer: Moving From Promise to Practical Application
Solving the PFIC Mystery: Genetic Testing and Diagnosis in Adults
Melanoma in Minutes: New Advances in Care—Available Through April 29
Melanoma in Minutes: Expert Strategies to Optimize Care—Available Through April 29
HelioLiver: Expanding Early Detection of Hepatocellular Carcinoma With AI
New Frontiers in Esophagogastric Cancer with Dr. Yelena Janjigian
The treatment of esophagogastric cancer is undergoing a profound transformation. In this episode, Yelena Janjigian, MD (MSKCC), discusses how perioperative chemoimmunotherapy and precision biomarkers are redefining the standard of care. Key highlights include: - The Perioperative Shift: Why starting immunotherapy before surgery is achieving unprecedented pathologic responses. - Precision Testing: The essential role of MSI, PD-L1, HER2, and CLDN18.2 testing for every patient. - Avoiding Understaging: Why clinical evaluation must go beyond imaging to prevent missed therapeutic opportunities. - Multidisciplinary Success: The critical need for surgeon-oncologist communication before the first incision. Tune in to learn why "cure" is the new benchmark in localized disease and how to integrate these advances into your clinical practice today. Interested in the complete CE activity? Complete Module 1: https://bit.ly/45u106o Complete Module 2: https://bit.ly/3HtOziO
HER2-Mutant NSCLC Update: Expanded Approval of Zongertinib
Click here to view the full CME/NCPD/CPE/AAPA activity and hear additional insights on the HER2-mutant NSCLC treatment landscape! https://i3health.com/course-information/nsclc-advances The FDA’s recent expanded approval of zongertinib marks a significant milestone in the treatment of non-small cell lung cancer (NSCLC). As the first oral human epidermal growth factor receptor 2 (HER2) inhibitor to move into the frontline setting, this therapy offers a new standard of care for patients with metastatic or unresectable non-squamous NSCLC harboring HER2 mutations. Following the approval, Beth Sandy, Thoracic Oncology Nurse Practitioner at the University of Pennsylvania, sat down to explore its clinical implications, including efficacy data, side effect management, and the potential of having a once-daily oral pill for improving patient experiences.
Choosing Not to Treat: How Do You Know When the Best Treatment Is No Treatment?
Choosing Not to Treat: How Do You Know When the Best Treatment Is No Treatment? by i3 Health
Additional Advances in Systemic Mastocytosis Research and Clinical Trials With Mariana Castells, MD, PhD
Stay ahead in Systemic Mastocytosis (SM) treatment! This interview, featuring Dr. Mariana Castells, explores the latest advancements in patient-centered care, including new drug approvals, multidisciplinary approaches, and crucial diagnostic updates. Learn how to shorten diagnosis times and improve long-term patient quality of life. Don't forget to take the activity and claim your credit after the episode! Click here to take module 1 of the activity: bit.ly/3Y3ivHM
The Future of Hemophilia: New Data, New Guidance, New Outcomes with Robert F. Sidonio, Jr., MD, MSc
Hemophilia care is evolving faster than ever. Dr. Robert Sidonio, Jr., a leading expert from Children’s Healthcare of Atlanta, joins us to discuss the latest breakthroughs in research and clinical trials. From navigating new treatment options to the importance of personalized patient selection, Dr. Sidonio shares the "real-world" perspective clinicians need to stay ahead. Listen now to discover what the future holds for hemophilia management! Click here to complete the activity, Raising the Bar for Hemophilia Management, and claim your CME credit: https://bit.ly/3Ini6vj
iNav: How AI-Driven Navigation Is Accelerating Pancreatic Cancer Care With Daniel King, MD, PhD, and Waqas Haque, MD, MPH
Read the full article at: https://oncdata.com/inav-daniel-king Pancreatic cancer remains one of oncology’s most challenging diseases—fast-moving, hard to detect early, and often diagnosed after curative options have narrowed. In this episode of Exploring AI in Oncology, Dr. Waqas Haque, Hematology/Oncology Fellow at the University of Chicago, speaks with Dr. Daniel King, Gastrointestinal Medical Oncologist at Northwell Health and co-inventor of iNav, an AI-enabled navigation platform designed to expedite diagnosis and treatment for patients with suspected pancreatic cancer.
Advancing Care in Systemic Mastocytosis: Expert Strategies with Dr. Mariana Castells - Module 2
Unlocking Systemic Mastocytosis: Expert Strategies with Dr. Mariana Castells - Module 1
Closing the Gaps in NET Diagnosis and Treatment: A Conversation With Aman Chauhan, MD
Neuroendocrine tumor (NET) care is changing fast—and the pace of innovation is only accelerating. In this episode, Aman Chauhan, MD, Associate Professor of Clinical Medicine at the University of California, San Francisco (UCSF), breaks down the latest advances that are reshaping how clinicians diagnose and treat NETs. Dr. Chauhan, who recently chaired i3 Health’s CME activity Optimizing Neuroendocrine Tumor Outcomes: Closing the Gaps in Diagnosis and Care, returns to highlight what’s new and what matters most for practice. From evolving epidemiologic insights to emerging targeted therapies and next‑generation immunotherapies, he explains how these developments are expanding options for patients and refining real‑world decision making. Whether you’re a clinician treating NETs, a trainee looking to stay current, or a listener interested in where cancer care is headed next, this conversation offers a concise, high‑yield tour of the NET landscape—and where it’s going next. Click the link to view the full activity and claim your free CME credit: https://bit.ly/41Qo65Y Click here to download/view the infographic: https://bit.ly/4bbSUmL
Molecular Testing Chaos: Are We Over Testing, Under Testing, or Testing the Wrong Things at the Wrong Time?
Read the full article on Oncology Data Advisor: https://oncdata.com/oncology-unfiltered-molecular-testing In the rapidly evolving landscape of modern oncology, molecular testing has emerged as one of the most powerful tools for personalizing patient care. However, this explosion of data has also created a "molecular testing chaos" that can overwhelm even the most seasoned clinicians. In this episode of Oncology Unfiltered, Melissa Cutrona, Co-Founder and General Manager of i3 Health and Oncology Data Advisor, sits down with Dr. Matthew Hadfield, Oncology Data Advisor Editor in Chief, to discuss whether we are over-testing, under-testing, or simply testing the wrong things at the wrong time. Thank you for watching Oncology Unfiltered. Check out our playlist and stay tuned for next month’s topic, “Molecular Testing Chaos: Are We Over-Testing, Under-Testing, or Testing the Wrong Things at the Wrong Time?”
If a Patient Can’t Afford to Fill the Prescription, Is It Really a Treatment Option?
Read the full article on Oncology Data Advisor: https://oncdata.com/oncology-unfiltered-financial-toxicity In this episode of Oncology Unfiltered, Melissa Cutrona, Co-Founder and General Manager of i3 Health and Oncology Data Advisor, and Matthew Hadfield, DO, Oncology Data Advisor Editor in Chief, explore how financial and geographic toxicities in oncology are, in reality, clinical toxicities. If a patient can’t afford to fill the prescription, is it really a treatment option? They discuss what financial toxicity truly means—far beyond drug prices—covering travel, parking, time off work, and the hidden costs of tests and therapies. Dr. Hadfield shares real-world examples of patients turning down innovative treatments and clinical trials because they can’t afford the logistical burden, and explains how geography and income create a two-tiered system of cancer care. The conversation examines how financial and geographic barriers distort shared decision making, limit participation in clinical trials, and skew our understanding of real-world efficacy. They also highlight the role of institutions, policymakers, and pharma in improving access, and why oncologists must reconsider ordering patterns, testing habits, and how they counsel patients about the full “cost” of care. Thank you for watching Oncology Unfiltered. Check out our playlist and stay tuned for next month’s topic, “Molecular Testing Chaos: Are We Over-Testing, Under-Testing, or Testing the Wrong Things at the Wrong Time?”
Living with Psoriatic Arthritis: A Patient’s Perspective on Biologics, Weight Loss & Early Diagnosis
Psoriatic arthritis management is evolving fast, but bridging the gap between clinical evidence and patient experience remains the ultimate challenge. When multidisciplinary teams and patients truly sync, care transforms. i3 Health recently convened a Multidisciplinary Task Force to discuss early screening, comorbidities, and therapeutic optimization. In this exclusive follow-up interview, we sit down with Archie Franklin, MBA—a veteran PsA patient and Task Force moderator—to go beyond the data. Listen now to hear a unique, dual-perspective look at the changing treatment landscape, sharing candid reflections on how clinicians can bridge communication gaps and practically elevate outcomes for every patient. Click the link to view the Task Force and claim your free CME/NCPD/CPE credit: https://bit.ly/4h5NSKb
Additional Advances in Melanoma Research and Clinical Trials With Michael A. Davies, MD, PhD + Module 2
The treatment landscape for melanoma continues to evolve at a rapid pace, with new clinical trial data and therapeutic modalities refining how clinicians approach both early-stage and advanced disease. Michael A. Davies, MD, PhD, Professor and Chairman of the Department of Melanoma Medical Oncology at the University of Texas MD Anderson Cancer Center, recently chaired i3 Health’s CME/NCPD/AAPA activity, "Melanoma in Minutes: Evidence-Driven Care for Improved Patient Outcomes." With numerous new developments in melanoma treatment over recent months, Dr. Davies sat down again to share these critical updates that are impacting practice. After the interview, stay tuned to hear module 2 of the full podcast activity. Click the link to complete module 2 and claim your free credit: bit.ly/44yO9RB